Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Seizert Capital Partners LLC

Key Points

• Seizert Capital Partners cut its position in Regeneron by 4.1% in Q4, selling 4,085 shares and now owning 94,705 shares (about 0.09% of the company) worth roughly $73.1 million, making REGN its sixth-largest holding (3.1% of the fund).
• Strong Q1 but mixed reaction: Regeneron beat Q1 estimates with revenue up ~19% and EPS of $9.47, and announced a $3 billion buyback, yet shares fell as net income slipped ~10% YoY and analysts issued both upgrades (Guggenheim to $995) and cuts (RBC to $762).
• Insider and institutional activity: Insiders sold 3,774 shares totaling about $2.94 million in the last three months (including sales by a director and an SVP); insiders own 7.02% of the company while institutional investors hold about 83.31%.

Seizert Capital Partners LLC cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 94,705 shares of the biopharmaceutical company's stock after selling 4,085 shares during the quarter. Regeneron Pharmaceuticals accounts for about 3.1% of Seizert Capital Partners LLC's holdings, making the stock its 6th biggest holding. Seizert Capital Partners LLC owned about 0.09% of Regeneron Pharmaceuticals worth $73,100,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in REGN. WPG Advisers LLC raised its holdings in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 25 shares during the last quarter. Board of the Pension Protection Fund bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Salomon & Ludwin LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $27,000. Torren Management LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $38,000. Finally, FNY Investment Advisers LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $38,000. 83.31% of the stock is currently owned by institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a "sector perform" stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today's weaker price action. Regeneron drops despite Q1 beat

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the business's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares of the company's stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the company's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,774 shares of company stock worth $2,942,738 in the last three months. Company insiders own 7.02% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $701.42 on Monday. The company has a market capitalization of $74.15 billion, a PE ratio of 17.09, a P/E/G ratio of 1.60 and a beta of 0.30. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The firm has a fifty day simple moving average of $756.81 and a 200 day simple moving average of $737.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts' consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business's revenue was up 19.0% compared to the same quarter last year. During the same period last year, the business posted $8.22 EPS. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.05 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be paid a $0.94 dividend. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.16%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. TD Cowen lifted their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a "buy" rating in a report on Thursday, April 23rd. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $825.00 to $800.00 and set an "equal weight" rating for the company in a report on Thursday. Zacks Research lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $800.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Finally, Barclays reduced their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating on the stock in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $826.59.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.